JX 2105
Alternative Names: JX-2105Latest Information Update: 10 Oct 2024
At a glance
- Originator Zhejiang Jingxin Pharmaceutical
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease